Related Experiment Videos
Interaction of mycophenolate mofetil and HLA matching on renal allograft survival
H U Meier-Kriesche1, A O Ojo, A B Leichtman
1Department of Medicine, The University of Michigan, Ann Arbor 48109-0364, USA.
Introduction:
The importance of HLA matching for renal transplantation outcomes has been appreciated for several decades. It has been hypothesized that as pharmacologic immunosuppression becomes stronger and more specific, the impact of HLA matching may be vanishing. Mycophenolate Mofetil (MMF) has been demonstrated to both decrease acute rejection and improve three-year graft survival. It is possible that with new immunosuppressive regimens containing MMF the relative effect of HLA matching may be altered. To determine the relative impact of HLA matching in patients on MMF we undertook an analysis of the United States Renal Transplant Data Registry (USRDS).
Methods:
All primary, solitary renal transplants registered at the USRDS between January 1995 and June 1997, on initial immunosuppression that included either MMF or AZA were followed until June 1998. Primary study end points were graft and patient survival. Kaplan-Meier analysis was performed to compare AZA vs. MMF treated patients by HLA mismatch. Cox proportional hazard models were used to investigate the interaction between HLA mismatch and AZA versus MMF therapy on the study endpoints. All multivariate analyses were corrected for 13 potential confounding pretransplant variables including intention to treat immunosuppression.
Results:
A total of 19,675 patients were analyzed (8,459 on MMF and 11,216 on AZA). Overall three year graft survival was higher in the MMF group when compared to the AZA group (87% vs. 84% respectively P<0.001). For both AZA and MMF three-year graft survival improved with fewer HLA donor-recipient mismatches. Comparing zero antigen mismatches to six antigen mismatches, the relative improvement was comparable for both patients on AZA (92.4% vs. 80.6%) and MMF (95.2% vs. 82.9%). By Cox proportional hazard model the relative risk for graft loss decreased significantly in both the AZA and MMF treated patients with increased HLA matching.
Conclusion:
The use of MMF does not obviate the benefits of HLA matching, while HLA matching does not minimize the benefits of MMF on long term graft survival. Our study would suggest that HLA matching and MMF therapy are additive factors in decreasing the risk for renal allograft loss.
Insights
Human Leukocyte Antigen (HLA) matching and Mycophenolate Mofetil (MMF) therapy are additive in improving renal transplant outcomes. Combining HLA matching with MMF offers enhanced graft survival by reducing allograft loss risk.
Area of Science:
- Nephrology
- Immunology
- Transplantation Science
Background:
- HLA matching is crucial for renal transplant success.
- Stronger immunosuppression may diminish HLA matching impact.
- Mycophenolate Mofetil (MMF) improves graft survival and reduces rejection.
Purpose of the Study:
- To assess the impact of HLA matching in renal transplant patients on MMF.
- To determine if MMF alters the relative effect of HLA matching.
- To analyze HLA matching's role in MMF-based immunosuppression.
Main Methods:
- Analysis of the United States Renal Transplant Data Registry (USRDS).
- Included primary renal transplants from 1995-1997 on MMF or Azathioprine (AZA).
- Kaplan-Meier and Cox proportional hazard models used for graft and patient survival analysis, adjusting for confounding variables.
Main Results:
- Overall three-year graft survival was higher with MMF (87%) vs. AZA (84%).
- Improved graft survival observed with fewer HLA mismatches in both MMF and AZA groups.
- Cox models showed reduced graft loss risk with increased HLA matching for both MMF and AZA patients.
Conclusions:
- MMF use does not negate the benefits of HLA matching.
- HLA matching does not diminish MMF's long-term graft survival benefits.
- HLA matching and MMF therapy are additive factors reducing renal allograft loss risk.